Skip to main content
eXit

ImmunoSensation leaves X

Due to recent developments, we decided to discontinue our activities on the social media plattform X. With this decision, we follow more than 60 german universities and other research institutions. As a Cluster of Excellence, we see the communication of research and scientific results as well as their discussion as one of our tasks, which is why we did not make this decision lightly. However, X's line is not compatible with the basic values that we represent and also want to live in our communication. These include transparency, constructive discourse and, above all, scientific integrity.

We are looking forward to welcome you on our channels at

Bluesky

LinkedIn

Instagram

facebook

youtube

 

Related news

News Icon

Publication

B cells maintain antigen presentation in the splenic marginal zone

—A team of international researchers, including ImmunoSensation³ members Prof. Niels Lemmermann and Prof. Andreas Schlitzer, shows that B cells support antiviral CD8⁺ T-cell responses beyond antibody production. In a murine CMV model, B-cell deficiency weakened virus-specific CD8⁺ T-cell responses. Mechanistically, B-cell-derived lymphotoxin β maintained CD169⁺ macrophages and Langerin⁺ cDC1 cells in the splenic marginal zone, enabling efficient T-cell priming. The study was published in Cellular & Molecular Immunology.
Full publication
Zwei Personen: Links Prof. Pröpstl und rechts Prof. Boztug

Honors & Funding

University of Bonn and University Hospital Bonn strengthen early-career clinical scientists

—The Faculty of Medicine at the University of Bonn and the University Hospital Bonn (UKB) are jointly launching the EKFS doctoral program IMMUNE PILOT, which introduces medical students to clinical-scientific research at an early stage. The structured program is positioned at the interface of immunology, neuroscience, and genetics and is aimed at students with a strong interest in research who aspire to pursue a career as clinician scientists. The program is funded by the Else Kröner-Fresenius Foundation (EKFS).
View entry
PrepAIred

Honors & Funding

Precise active ingredients against pancreatic cancer

—Pancreatic cancer remains one of the deadliest forms of cancer. At the German Cancer Congress 2026, German Cancer Aid is now presenting three large-scale projects that it is funding as part of its “German Alliance for Pancreatic Cancer” funding priority. In the funded project PrepAIred, Bonn researchers , in cooperation with the University of North Carolina (USA), want to use AI-based protein design to specifically combat pancreatic cancer. German Cancer Aid is funding the project with a total of 1.99 million euros over a period of four years.
View entry

Back to the news overview